Projects per year
Personal profile
Expertise
Project: " Targeting of tumor subpopulations in Multiple Myeloma: protein/gene expression analysis of residual cancer cells and targeting of these cells using nanobodies"
I obtained a Master in Biomedical Sciences at the Free University of Brussels (Vrije Universiteit Brussel, VUB) in 2011. I started my PhD in the lab of Hematology and Immunology (HEIM) under the supervision of Prof. Karin Vanderkerken focusing on the role of the bone marrow microenvironment in multiple myeloma drug resistance. I participated in an EU FP7 project (OVER-MyR) and investigated different cell types that contribute to myeloma disease including myeloid-derived suppressor cells (supervised by Prof. Els Van Valckenborgh), cancer associated fibroblasts (supervised by Prof. Eline Menu and Prof. Angelo Vacca) and mesenchymal stromal cells (supervised by Prof. Ivan Van Riet). In 2016, I obtained a FWO grant to continue my work as a post-doctoral researcher at the HEIM department and in 2018I became assistant professor (10%) at the VUB.
My project focuses on the use of antigen-specific nanobodies to target residual disease in myeloma and prevent relapse of patients. In collaboration with Prof Peter Croucher (Garvan Institute, Sydney, Australia), we investigate myeloma cell dormancy in vitro and in vivo. Nationally, I closely collaborate with Profs Nick Devoogdt and Matthias D’Huyvetter for the development and characterization of AXL- and CS1 specific nanobodies to target minimal residual disease in myeloma by targeted radionuclide therapy (TRNT).
Fingerprint
Dive into the research topics where Kim De Veirman is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
HERC66: 3D-CELLMAP: Unveiling complex cellular interactions in tissues through 3D super-resolution protein multiplex imaging
Movahedi, K., Rooman, I., Sermon, K., De Bundel, D., Fioravanti, A., Staels, W., Magez, S., Breckpot, K., De Kock, J., Laoui, D., Goyvaerts, C., Smolders, I., Van Ginderachter, J., Marcelino Rodrigues, R., De Leu, N., van Grunsven, L., Hernot, S., Peeters, E., Vanhaecke, T., De Veirman, K., Ruytinx, J., Van Schependom, J., Kortekaas, I. & Goossens, E.
1/05/24 → 31/05/28
Project: Fundamental
-
OZR4286: Financiering MZW OZR: DELI-SORT: MACSQuant® Tyto for sterile DELicate Immune cells SORTing
Laoui, D., Vanginderachter, J. A., Magez, S., Tuyaerts, S., Fioravanti, A., Devoogdt, N., Van der Henst, C., Raes, G., Stijlemans, B., Hadadi, E., De Trez, C., Ruytinx, J., Brunner, J., De Groof, T. & De Veirman, K.
24/04/24 → 24/04/28
Project: Fundamental
-
OZR4288: Financiering MZW OZR: RAPTOR: Rapid Analysis and production of Proteins for clinical Translation using biacORe and bioreactOR systems.
Devoogdt, N., Hernot, S., De Groof, T., Ballet, S., Stijlemans, B., Massie, A., Rooman, I., Keyaerts, M., Raes, G., De Kock, J., Breckpot, K., De Veirman, K. & Caveliers, V.
24/04/24 → 24/04/28
Project: Fundamental
-
ANI322: NANO-AXL: Nanobody-based imaging and targeting of AXL positive tumor cells in Acute Myeloid Leukemia and Multiple Myeloma
1/01/23 → 31/12/26
Project: Fundamental
-
FWOAL1045: Nanobody-based AXL targeting and combination treatment for acute myeloid leukemia and multiple myeloma
De Veirman, K., Devoogdt, N. & Vanderkerken, K.
1/01/22 → 31/12/25
Project: Fundamental
Research output
-
Activated cDCs by anti-CD40 agonist therapy induce anti-tumor effectsin Multiple Myeloma
Verheye, E., Kancheva, D., Satilmis, H., Vandewalle, N., Fan, R., Bardet, P., Clappaert, E., Vanderkerken, K., De Veirman, K. & Laoui, D., 2024, (Unpublished).Research output: Unpublished contribution to conference › Poster
-
Adrenergic signaling activates the tumor immune microenvironment in Multiple Myeloma
Satilmis, H., Verheye, E., Vandewalle, N., De Bruyne, E., Menu, E., Vanderkerken, K. & De Veirman, K., 1 Feb 2024, (Unpublished).Research output: Unpublished contribution to conference › Poster
-
Adrenergic signaling activates the tumor immune microenvironment in Multiple Myeloma
Satilmis, H., Verheye, E., Vandewalle, N., De Bruyne, E., Menu, E., Vanderkerken, K. & De Veirman, K., 30 May 2024, (Unpublished).Research output: Unpublished contribution to conference › Poster
-
Anti-Idiotypic VHHs and VHH-CAR-T Cells to Tackle Multiple Myeloma: Different Applications Call for Different Antigen-Binding Moieties
Hanssens, H., Meeus, F., Gesquiere, E. L., Puttemans, J., Vlaeminck, Y. D., Veirman, K. D., Breckpot, K. & Devoogdt, N., 22 May 2024, In: International Journal of Molecular Sciences. 25, 11, 16 p., 5634.Research output: Contribution to journal › Article › peer-review
Open Access -
AXL-specific single domain antibodies show diagnostic potential and anti-tumor activity in Acute Myeloid Leukemia
Vandewalle, N., Satilmis, H., Verheye, E., Fan, R., Wang, Y., De Groof, T., Bridoux, J., kerre, T., De Beule, N., De Becker, A., De Bruyne, E., Menu, E., Vanderkerken, K., Breckpot, K., Devoogdt, N. & De Veirman, K., 15 Apr 2024, In: Theranostics. 14, 7, p. 2656-2674 19 p.Research output: Contribution to journal › Article › peer-review
Open Access
Prizes
-
ASH abstract Achievement Award 2014
De Veirman, Kim (Recipient), 6 Dec 2014
Prize: National/international honour
-
ASH abstract Achievement Award 2019
De Veirman, Kim (Recipient), 2019
Prize: National/international honour
-
Best Poster Presentation
Vandewalle, Niels (Recipient), Menu, Eline (Recipient), De Bruyne, Elke (Recipient), De Veirman, Kim (Recipient), Breckpot, Karine (Recipient) & Devoogdt, Nick (Recipient), 2 Feb 2024
Prize: Prize (including medals and awards)
-
Development of a nanoCAR-T cell approach for the treatment of multiple myeloma
Hanssens, Heleen (Recipient), Devoogdt, Nick (Recipient), De Veirman, Kim (Recipient) & Breckpot, Karine (Recipient), 15 Dec 2021
Prize: Fellowship awarded competitively
-
Poster award Belgian Hematological Society 30th Annual General Meeting 2015
De Veirman, Kim (Recipient), 29 Jan 2015
Prize: National/international honour
Activities
-
AXL-specific single domain antibodies show diagnostic potential and anti-tumor activity in Acute Myeloid Leukemia
Niels Vandewalle (Presenter), Hatice Satilmis (Contributor), Emma Verheye (Contributor), Yanmeng Wang (Contributor), Timo De Groof (Contributor), Nathan De Beule (Contributor), Tessa kerre (Contributor), Nathan De Beule (Contributor), Ann De Becker (Contributor), Elke De Bruyne (Contributor), Eline Menu (Contributor), Karin Vanderkerken (Contributor), Karine Breckpot (Contributor), Nick Devoogdt (Contributor) & Kim De Veirman (Contributor)
12 Mar 2024Activity: Talk or presentation › Talk or presentation at a conference
-
AXL targeting using Bemcentinib increases chemosensitivity in Acute Myeloid Leukemia
Niels Vandewalle (Speaker), Laura Meysman (Contributor), Nathan De Beule (Contributor), Ann De Becker (Contributor), Hatice Satilmis (Contributor), Emma Verheye (Contributor), Rong Fan (Contributor), Elke De Bruyne (Contributor), Eline Menu (Contributor), Karin Vanderkerken (Contributor), Karine Breckpot (Contributor), Nick Devoogdt (Contributor) & Kim De Veirman (Contributor)
3 Feb 2023Activity: Talk or presentation › Talk or presentation at a conference
-
Mapping the immune heterogeneity within the myeloma microenvironment using single-cell transcriptomics
Emma Verheye (Speaker), Rong Fan (Contributor), Hatice Satilmis (Contributor), Niels Vandewalle (Contributor), Pauline Bardet (Contributor), Emile Clappaert (Contributor), Daliya Kancheva (Contributor), Elke De Bruyne (Contributor), Karin Vanderkerken (Contributor), Kim De Veirman (Contributor) & Damya Laoui (Contributor)
3 Feb 2023Activity: Talk or presentation › Talk or presentation at a conference
-
Targeting of pyrroline-5-carboxylate reductase (PYCR) reduces drug resistance in multiple myeloma in vitro.
Inge Oudaert (Speaker), Eline Menu (Contributor) & Kim De Veirman (Contributor)
29 Jan 2021 → 30 Jan 2021Activity: Talk or presentation › Talk or presentation at a conference
-
AXL: A potential therapeutic target to improve chemosensitivity in Multiple Myeloma (BACR Annual Meeting 2020)
Kim De Veirman (Contributor) & Niels Vandewalle (Speaker)
7 Feb 2020Activity: Talk or presentation › Talk or presentation at a conference
Thesis
-
Assessment of antigen-binding domain parameters important for adequate CAR-T-cell activation: evaluating different SLAMF7-targeting nanobodies.
Author: Meeus, F., Hanssens, H., De Veirman, K. & Devoogdt, N., 19 Jun 2020Supervisor: Hanssens, H. (Advisor)
Student thesis: Master's Thesis
-
AXL and CS1: New targets in myeloma cell dormancy
Author: De Veirman, K. & Benalla, S., 21 Jun 2018Student thesis: Master's Thesis
-
Development of a NanoCAR approach for the treatment of multiple myeloma
Author: Devoogdt, N., Breckpot, K., De Veirman, K. & Hanssens, H., 2022Student thesis: Doctoral Thesis
-
Mesenchymal Stromal Cell induced hedgehog signaling in Multiple Myeloma and its role in drug resistance
Author: De Veirman, K. & Terwecoren, D., 2013Student thesis: Master's Thesis
-
Nanobody-based individualized AXL targeting to reverse immune suppression and overcome therapy resistance in Acute Myeloid Leukemia.
Author: De Veirman, K., Breckpot, K., Devoogdt, N. & Kerre, T., 2024Student thesis: Doctoral Thesis